Long noncoding RNAs in key cellular processes involved in aortic aneurysms

Zhi-yuan Wu, Matthias Trenner, Reinier A. Boon, Joshua M. Spin, Lars Maegdefessel

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.
Original languageEnglish
Pages (from-to)112-118
JournalAtherosclerosis
Volume292
DOIs
Publication statusPublished - 2020

Cite this

Wu, Zhi-yuan ; Trenner, Matthias ; Boon, Reinier A. ; Spin, Joshua M. ; Maegdefessel, Lars. / Long noncoding RNAs in key cellular processes involved in aortic aneurysms. In: Atherosclerosis. 2020 ; Vol. 292. pp. 112-118.
@article{830a50f9b7ec4abebba6840342a3f45b,
title = "Long noncoding RNAs in key cellular processes involved in aortic aneurysms",
abstract = "Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.",
keywords = "Aortic aneurysm, Long noncoding RNA, Non-coding RNA, Smooth muscle cells, Vascular disease",
author = "Zhi-yuan Wu and Matthias Trenner and Boon, {Reinier A.} and Spin, {Joshua M.} and Lars Maegdefessel",
year = "2020",
doi = "10.1016/j.atherosclerosis.2019.11.013",
language = "English",
volume = "292",
pages = "112--118",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

Long noncoding RNAs in key cellular processes involved in aortic aneurysms. / Wu, Zhi-yuan; Trenner, Matthias; Boon, Reinier A.; Spin, Joshua M.; Maegdefessel, Lars.

In: Atherosclerosis, Vol. 292, 2020, p. 112-118.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Long noncoding RNAs in key cellular processes involved in aortic aneurysms

AU - Wu, Zhi-yuan

AU - Trenner, Matthias

AU - Boon, Reinier A.

AU - Spin, Joshua M.

AU - Maegdefessel, Lars

PY - 2020

Y1 - 2020

N2 - Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.

AB - Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.

KW - Aortic aneurysm

KW - Long noncoding RNA

KW - Non-coding RNA

KW - Smooth muscle cells

KW - Vascular disease

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075501490&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31785492

U2 - 10.1016/j.atherosclerosis.2019.11.013

DO - 10.1016/j.atherosclerosis.2019.11.013

M3 - Review article

VL - 292

SP - 112

EP - 118

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -